Last update :
19/11/2024
Anticancer drug   Blinatumomab  
injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Blincyto Argentina, Australia, Austria, Belgium, Brazil, Chile, Denmark, France, Germany, Great Britain, Hungary, Ireland, Italy, Japan, Luxembourg, Mexico, Norway, Peru, Romania, Slovenia, Spain, Sweden, Switzerland, United States of America
References   injection   References : Blinatumomab  
Type Publication
2296 Manufacturer Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3774 Manufacturer Blinatumomab - (Blincyto®) - Summary of Product Characteristics
Amgen 2016
3976 Journal Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218

  Mentions Légales